MA50373A - Anticorps anti-c5 présentant une pharmacocinétique améliorée - Google Patents
Anticorps anti-c5 présentant une pharmacocinétique amélioréeInfo
- Publication number
- MA50373A MA50373A MA050373A MA50373A MA50373A MA 50373 A MA50373 A MA 50373A MA 050373 A MA050373 A MA 050373A MA 50373 A MA50373 A MA 50373A MA 50373 A MA50373 A MA 50373A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- improved pharmacokinetics
- pharmacokinetics
- improved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461949932P | 2014-03-07 | 2014-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50373A true MA50373A (fr) | 2020-08-19 |
Family
ID=52684742
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38859A MA38859B1 (fr) | 2014-03-07 | 2015-03-06 | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
MA050373A MA50373A (fr) | 2014-03-07 | 2015-03-06 | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38859A MA38859B1 (fr) | 2014-03-07 | 2015-03-06 | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
Country Status (29)
Country | Link |
---|---|
US (10) | US9079949B1 (fr) |
EP (3) | EP2970455B1 (fr) |
JP (5) | JP6112469B1 (fr) |
KR (4) | KR101796886B1 (fr) |
CN (2) | CN113416254A (fr) |
AR (1) | AR099698A1 (fr) |
AU (4) | AU2015226977B2 (fr) |
BR (1) | BR112016020454B1 (fr) |
CA (2) | CA3166772A1 (fr) |
CY (1) | CY1118018T1 (fr) |
DK (2) | DK3095795T3 (fr) |
EA (2) | EA202090275A3 (fr) |
ES (2) | ES2749978T3 (fr) |
HK (1) | HK1217207A1 (fr) |
HR (1) | HRP20161146T1 (fr) |
HU (2) | HUE030944T2 (fr) |
IL (4) | IL296502A (fr) |
LT (1) | LT2970455T (fr) |
MA (2) | MA38859B1 (fr) |
ME (1) | ME02629B (fr) |
MX (2) | MX368909B (fr) |
NZ (2) | NZ631007A (fr) |
PL (2) | PL3095795T3 (fr) |
PT (2) | PT3095795T (fr) |
RS (1) | RS55386B1 (fr) |
SI (2) | SI2970455T1 (fr) |
SM (1) | SMT201600366B (fr) |
TW (2) | TWI667256B (fr) |
WO (1) | WO2015134894A1 (fr) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
SI2275443T1 (sl) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
WO2013047748A1 (fr) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
SG11201402750SA (en) | 2011-11-30 | 2014-10-30 | Chugai Pharmaceutical Co Ltd | Drug containing carrier into cell for forming immune complex |
KR102336895B1 (ko) | 2012-02-20 | 2021-12-08 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
TWI766493B (zh) | 2012-08-24 | 2022-06-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
WO2014163101A1 (fr) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Variant de région fc |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
CA2964857A1 (fr) * | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methodes de prediction de taux de medicaments anti-tnf alpha et formation d'autoanticorps |
US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
EP3981794A1 (fr) | 2014-12-19 | 2022-04-13 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-c5 et leurs procédés d'utilisation |
KR20180054923A (ko) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
EP3247723A1 (fr) * | 2015-01-22 | 2017-11-29 | Chugai Seiyaku Kabushiki Kaisha | Combinaison de deux anticorps anti-c5 ou plus et ses procédés d'utilisation |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
MX2017010858A (es) | 2015-02-27 | 2017-12-11 | Chugai Pharmaceutical Co Ltd | Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6. |
JP7133925B2 (ja) * | 2015-03-23 | 2022-09-09 | アレクシオン ファーマシューティカルズ インコーポレイテッド | ウイルス濾過 |
EP3277715A2 (fr) * | 2015-03-31 | 2018-02-07 | Alexion Pharmaceuticals, Inc. | Identification et traitement de sous-populations de patients souffrant d'hémoglobinurie paroxystique nocturne |
WO2016178980A1 (fr) | 2015-05-01 | 2016-11-10 | Alexion Pharmaceuticals, Inc. | Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par les anticorps chez des receveurs sensibilisés d'une greffe de rein |
JP2018516678A (ja) | 2015-06-04 | 2018-06-28 | メディモップ・メディカル・プロジェクツ・リミテッド | 薬物送達装置用カートリッジ挿入 |
WO2017044811A1 (fr) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Variants d'éculizumab et d'éculizumab glycosylé de recombinaison |
EP3349773A4 (fr) | 2015-09-14 | 2019-05-01 | Cincinnati Children's Hospital Medical Center | Méthodes et compositions pour le traitement de la maladie de gaucher par l'intermédiaire de la modulation du récepteur c5a |
WO2017062649A1 (fr) | 2015-10-07 | 2017-04-13 | Alexion Pharmaceuticals, Inc. | Procédé pour le traitement de la dégénérescence maculaire liée à l'âge chez un patient |
EP3359555B1 (fr) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Régimes posologiques |
JP7221691B2 (ja) * | 2015-10-30 | 2023-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | T細胞媒介性同種移植片血管障害の増悪を抑制する方法 |
KR101789973B1 (ko) * | 2015-12-18 | 2017-10-26 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
US20200270363A1 (en) * | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
WO2017123636A1 (fr) * | 2016-01-11 | 2017-07-20 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour traitement |
EP3408291A1 (fr) * | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anticorps anti-c5 à commutation ph améliorée |
PL234632B1 (pl) * | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
EP3909609A1 (fr) * | 2016-05-27 | 2021-11-17 | Alexion Pharmaceuticals, Inc. | Procédés de traitement de la myasthénie grave généralisée réfractaire |
RU2018146778A (ru) | 2016-06-07 | 2020-07-09 | Новартис Аг | Режим дозирования антитела к c5 |
JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗c5抗体及びそれらの使用 |
KR101852739B1 (ko) * | 2016-06-17 | 2018-04-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
US20190276524A1 (en) | 2016-10-12 | 2019-09-12 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
ES2848206T3 (es) | 2016-10-19 | 2021-08-05 | Alexion Pharma Inc | Un método de cuantificar C5 sin unir en una muestra |
WO2018081400A1 (fr) | 2016-10-27 | 2018-05-03 | Alexion Pharmaceuticals Inc. | Dosage de dépôt de c5b-9 dans des troubles associés au complément |
BR112019011769A2 (pt) * | 2016-12-16 | 2019-11-12 | Samsung Bioepis Co Ltd | composição de anticorpo anti-c5 aquosa estável |
US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
IL307593A (en) * | 2017-01-31 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Pharmaceutical preparation for use in the treatment and prevention of C5-related diseases and methods for the treatment and prevention of C5-related diseases |
SG11201908238SA (en) * | 2017-03-06 | 2019-10-30 | The Trustees Of The Univ Of Pensylvania | Anti-c5 antibodies and uses thereof |
JP7247099B2 (ja) * | 2017-03-31 | 2023-03-28 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒト血清または尿におけるalxn1210およびエクリズマブの同時定量のための方法 |
MX2019012033A (es) * | 2017-04-07 | 2019-12-05 | Apellis Pharmaceuticals Inc | Regímenes de dosificación y composiciones y métodos relacionados. |
JP2020517605A (ja) | 2017-04-19 | 2020-06-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗c5抗体の有効性 |
EP3615564A1 (fr) | 2017-04-24 | 2020-03-04 | Alexion Pharmaceuticals, Inc. | Protéines de fusion d'inhibiteur de cellules immunitaires d'anticorps |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
EP3630844A4 (fr) * | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | Nouvel anticorps anti-c-met et son utilisation |
AU2018301412A1 (en) * | 2017-07-11 | 2020-01-30 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof |
EP3658184B1 (fr) * | 2017-07-27 | 2023-09-06 | Alexion Pharmaceuticals, Inc. | Formules d'anticorps anti-c5 à haute concentration |
WO2019070714A1 (fr) * | 2017-10-04 | 2019-04-11 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de patients présentant une glomérulonéphrite membranoproliférative |
KR20200070355A (ko) * | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
SG11202005181RA (en) * | 2017-12-04 | 2020-07-29 | Ra Pharmaceuticals Inc | Modulators of complement activity |
KR20200098528A (ko) | 2017-12-13 | 2020-08-20 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 조합물 및 이의 용도 |
CN111683703B (zh) | 2017-12-22 | 2022-11-18 | 西氏医药包装(以色列)有限公司 | 适用于不同尺寸的药筒的注射器 |
WO2019143761A1 (fr) * | 2018-01-17 | 2019-07-25 | Children's Hospital Medical Center | Compositions et méthodes pour le traitement du syndrome de hunter |
WO2019231983A1 (fr) | 2018-05-31 | 2019-12-05 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) chez des patients pédiatriques |
EP3802603A1 (fr) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement du syndrome hémolytique et urémique atypique (shua) chez des patients pédiatriques |
MA52969A (fr) * | 2018-06-19 | 2021-04-28 | Atarga Llc | Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations |
EP3814373A1 (fr) | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Procédés de production d'anticorps anti-c5 |
WO2020041301A1 (fr) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément |
CA3111396A1 (fr) * | 2018-09-06 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | Anticorps humanises anti-c5 et leurs utilisations |
EP3852874A1 (fr) | 2018-09-17 | 2021-07-28 | Kyoto University | Administration d'un agent anti-c5 pour le traitement d'une lésion ou d'une insuffisance hépatique |
EP3852876A1 (fr) | 2018-09-21 | 2021-07-28 | Alexion Pharmaceuticals, Inc. | Éculuzimab pour le traitement de la neuromyélite optique |
EP3863657A4 (fr) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | Protéines de fusion bifonctionnelles et utilisations associées |
WO2020092546A1 (fr) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration d'une hyaluronidase et d'un anticorps anti-c5 pour le traitement d'états associés au complément |
WO2020092549A1 (fr) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Dosage et administration par voie sous-cutanée d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) |
WO2020106724A1 (fr) | 2018-11-20 | 2020-05-28 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la myasthénie grave généralisée réfractaire chez des patients pédiatriques |
LT3914617T (lt) | 2019-01-25 | 2024-05-27 | Alexion Pharmaceuticals, Inc. | Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus) |
US11642470B2 (en) * | 2019-02-11 | 2023-05-09 | West Pharma. Services IL, Ltd. | Anti-C5 antibody dispensing injector and method of injection |
EP3924380A1 (fr) | 2019-02-14 | 2021-12-22 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de la myasthénie grave généralisée |
CA3137907A1 (fr) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Anticorps anti-c5 humanises bi-fonctionnels et proteines de fusion du facteur h et leurs utilisations |
US20220227851A1 (en) | 2019-05-24 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Methods of treating vitiligo using an anti-c5 antibody |
WO2021026160A1 (fr) | 2019-08-05 | 2021-02-11 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la myasthénie grave généralisée réfractaire avec de l'eculizumab |
US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
JP2023501377A (ja) | 2019-11-08 | 2023-01-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 高濃度抗c5抗体配合物 |
CA3161271A1 (fr) * | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Anticorps anti-c5 pour le traitement de trouble du spectre de la neuromyelite optique |
WO2021133660A1 (fr) | 2019-12-23 | 2021-07-01 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement du syndrome urémique hémolytique atypique associé à la grossesse à l'aide d'un anticorps anti-c5 |
US20230416344A1 (en) | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
BR112022021136A2 (pt) | 2020-04-30 | 2022-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas |
JP2023526051A (ja) | 2020-05-12 | 2023-06-20 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 発作性夜間ヘモグロビン尿症の処置のための補体d因子阻害剤の単独又は抗c5抗体との組み合わせでの使用 |
CN115667925A (zh) | 2020-05-15 | 2023-01-31 | 阿雷克森制药公司 | 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途 |
CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
CN116194478A (zh) * | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下(sc)施用抗c5抗体治疗补体相关病症 |
WO2021263056A1 (fr) * | 2020-06-25 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de la sclérose latérale amyotrophique |
EP4178674A1 (fr) | 2020-07-09 | 2023-05-17 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) chez des patients pédiatriques |
KR20230047179A (ko) | 2020-08-13 | 2023-04-06 | 알렉시온 파마슈티칼스, 인코포레이티드 | 조혈 줄기세포 이식-연관 혈전성 미세혈관병증(hsct-tma)을 치료하기 위한 항-c5 항체의 복용량 및 투여 |
EP4213940A1 (fr) | 2020-09-21 | 2023-07-26 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de la néphrite glomérulaire à médiation par c5 (gn), y compris la néphrite lupique (ln) et/ou la néphropathie à l'iga (igan) |
JP2023548046A (ja) | 2020-10-23 | 2023-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗c5抗体を使用する、補体障害を有する患者の処置方法 |
JP2023552456A (ja) * | 2020-12-07 | 2023-12-15 | インベテックス インコーポレイテッド | 治療薬の家畜動物における半減期を増加させるための組成物及びその使用方法 |
CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
EP4267612A1 (fr) * | 2020-12-25 | 2023-11-01 | The Trustees of the University of Pennsylvania | Anticorps anti-c5 humanisés et protéines de fusion du facteur h et leurs utilisations |
WO2022159373A1 (fr) | 2021-01-22 | 2022-07-28 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la microangiopathie thrombotique à médiation par le complément à l'aide d'un anticorps anti-c5 |
JP2024520497A (ja) | 2021-05-28 | 2024-05-24 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Cm-tmaバイオマーカーを検出するための方法 |
WO2022265915A1 (fr) | 2021-06-14 | 2022-12-22 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de la dermatomyosite (dm) |
WO2023287991A1 (fr) | 2021-07-14 | 2023-01-19 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour le traitement de la myasthénie gravis |
WO2023023220A1 (fr) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément |
EP4402174A1 (fr) | 2021-09-17 | 2024-07-24 | Novartis AG | Méthodes de prévention du rejet de greffe dans une xénogreffe |
CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B(CFB)iRNA组合物及其使用方法 |
WO2024054408A1 (fr) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Dosage supplémentaire et administration d'anticorps anti-c5 pour le traitement de la microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) |
WO2024054436A1 (fr) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Profils de biomarqueurs de diagnostic et de pronostic chez des patients ayant une microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) |
WO2024072798A1 (fr) | 2022-09-28 | 2024-04-04 | Alexion Pharmaceuticals, Inc. | Dosage et administration d'anticorps anti-c5 pour prévenir ou réduire au minimum une lésion rénale aiguë associée à une chirurgie cardiaque (csa-aki) et/ou des événements rénaux indésirables majeurs (make) ultérieurs chez des patients atteints d'une maladie rénale chronique |
CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
EP0228458B2 (fr) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Cellules epitheliales exprimant un materiau genetique etranger |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
JP2703764B2 (ja) * | 1986-04-28 | 1998-01-26 | シータス オンコロジー コーポレイション | 補体成分C5aに対するモノクローナル抗体 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
WO1989005345A1 (fr) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Modification genetique de cellules endotheliales |
WO1989007136A2 (fr) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Hepatocytes modifies et leurs utilisations |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
GB9026191D0 (en) | 1990-12-01 | 1991-01-16 | Harris Pharma Ltd | Breath actuated dispensing device |
CA2110799A1 (fr) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Fragments d'anticorps d'origine microbienne, et conjugues |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ATE165862T1 (de) | 1992-07-23 | 1998-05-15 | Minnesota Mining & Mfg | Geformte schleifteilchen und verfahren zur ihrer herstellung |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2322324T3 (es) | 1992-08-21 | 2009-06-19 | Vrije Universiteit Brussel | Inmumoglobulinas desprovistas de cadenas ligeras. |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
IT1265573B1 (it) | 1993-09-17 | 1996-11-22 | Zanussi Grandi Impianti Spa | Forno di cottura di alimenti con porta perfezionata |
US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
EP2036541A1 (fr) | 1994-03-07 | 2009-03-18 | Nektar Therapeutics | Procédés et compositions pour l'administration pulmonaire d'insuline |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP0859841B1 (fr) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Banques de proteines/(poly)peptides |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
WO1997042217A1 (fr) | 1996-05-06 | 1997-11-13 | The Uab Research Foundation | Toxines de fusion radiomarquees pour therapies contre le cancer |
US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
GB9626960D0 (en) | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998047531A2 (fr) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Anticorps monoclonaux anti-cd3 ne se liant pas au recepteur fc, fournissant un signal tcr partiel et induisant l'anergie clonale |
US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
CA2369262A1 (fr) | 1999-04-13 | 2000-10-19 | Sudha Nagarajan | Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite |
WO2000061178A1 (fr) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite |
US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
DK1313415T3 (da) | 2000-08-30 | 2008-10-13 | Univ Johns Hopkins | Indretninger til intraokulær lægemiddeladministration |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
WO2003015819A1 (fr) * | 2001-08-17 | 2003-02-27 | Tanox, Inc. | Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b |
CN100349629C (zh) | 2001-09-12 | 2007-11-21 | 贝克顿迪肯森公司 | 用于药物传送的微针为基础的笔装置和使用该装置的方法 |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
EP3150630A1 (fr) | 2002-09-27 | 2017-04-05 | Xencor Inc. | Variantes fc optimisées et leurs procédés de génération |
FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
WO2004073551A2 (fr) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Dispositif d'administration transsclerale de medicament et procedes associes |
AU2004261229A1 (en) | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005077981A2 (fr) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Polypeptides fc a nouveaux sites de liaison de ligands fc |
EP2053062A1 (fr) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Variantes d'immunoglobine en dehors de la région Fc |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060234303A1 (en) | 2005-03-03 | 2006-10-19 | Xencor, Inc. | Methods for the design of libraries of protein variants |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
CA2634131C (fr) | 2005-12-21 | 2014-02-11 | Wyeth | Formulations de proteines a viscosite reduite et leurs utilisations |
WO2007103134A2 (fr) | 2006-03-02 | 2007-09-13 | Alexion Pharmaceuticals, Inc. | Prolongation de la survie d'un allogreffon par inhibition d'activite complementaire |
AU2007225044C1 (en) * | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
WO2008048545A2 (fr) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molécules ayant des demi-vies réduites, compositions et leurs utilisations |
WO2008092117A2 (fr) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Nouvelles insertions, délétions et substitutions d'immunoglobulines |
US20090110679A1 (en) | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
PT2808343T (pt) | 2007-12-26 | 2019-09-04 | Xencor Inc | Variantes fc com ligação alterada a fcrn |
SI2275443T1 (sl) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul |
CN110317272A (zh) | 2008-10-14 | 2019-10-11 | 霍夫曼-拉罗奇有限公司 | 免疫球蛋白变体及其用途 |
AU2009313203B2 (en) * | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP2445937B1 (fr) * | 2009-06-23 | 2017-05-24 | Alexion Pharmaceuticals, Inc. | Anticorps bispécifiques se liant aux protéines du complément |
EP2496259B1 (fr) * | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Traitement de l'hémoglobinurie paroxystique nocturne |
SA111320266B1 (ar) * | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN105963694B (zh) * | 2010-04-30 | 2019-11-05 | 阿雷克森制药公司 | 抗-c5a抗体和使用所述抗体的方法 |
SG185107A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Antibodies having reduced immunogenicity in a human |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
WO2012088247A2 (fr) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Fragments et anticorps anti-c5/c5a/c5adesr |
EP2698431B1 (fr) | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Rétention de molécules de liaison à l'antigène dans le plasma sanguin et procédé de modification du caractère immunogène |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2013047748A1 (fr) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques |
US10011660B2 (en) * | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EP3277715A2 (fr) | 2015-03-31 | 2018-02-07 | Alexion Pharmaceuticals, Inc. | Identification et traitement de sous-populations de patients souffrant d'hémoglobinurie paroxystique nocturne |
WO2016178980A1 (fr) | 2015-05-01 | 2016-11-10 | Alexion Pharmaceuticals, Inc. | Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par les anticorps chez des receveurs sensibilisés d'une greffe de rein |
JP7221691B2 (ja) | 2015-10-30 | 2023-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | T細胞媒介性同種移植片血管障害の増悪を抑制する方法 |
JP7102353B2 (ja) * | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗c5抗体及びそれらの使用 |
US20190276524A1 (en) | 2016-10-12 | 2019-09-12 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
-
2014
- 2014-09-11 NZ NZ631007A patent/NZ631007A/en unknown
- 2014-09-11 NZ NZ711451A patent/NZ711451A/en unknown
-
2015
- 2015-03-06 BR BR112016020454-9A patent/BR112016020454B1/pt active IP Right Grant
- 2015-03-06 PT PT161776562T patent/PT3095795T/pt unknown
- 2015-03-06 KR KR1020167027411A patent/KR101796886B1/ko active IP Right Grant
- 2015-03-06 TW TW104107187A patent/TWI667256B/zh active
- 2015-03-06 AR ARP150100697A patent/AR099698A1/es unknown
- 2015-03-06 CN CN202110517494.0A patent/CN113416254A/zh active Pending
- 2015-03-06 ES ES16177656T patent/ES2749978T3/es active Active
- 2015-03-06 HU HUE15710396A patent/HUE030944T2/en unknown
- 2015-03-06 AU AU2015226977A patent/AU2015226977B2/en active Active
- 2015-03-06 CA CA3166772A patent/CA3166772A1/fr active Pending
- 2015-03-06 RS RS20160996A patent/RS55386B1/sr unknown
- 2015-03-06 KR KR1020217011897A patent/KR102539636B1/ko active IP Right Grant
- 2015-03-06 PL PL16177656T patent/PL3095795T3/pl unknown
- 2015-03-06 WO PCT/US2015/019225 patent/WO2015134894A1/fr active Application Filing
- 2015-03-06 SI SI201530009A patent/SI2970455T1/sl unknown
- 2015-03-06 KR KR1020177032026A patent/KR102304136B1/ko active IP Right Grant
- 2015-03-06 TW TW108122663A patent/TWI708785B/zh active
- 2015-03-06 PL PL15710396T patent/PL2970455T3/pl unknown
- 2015-03-06 CA CA2942165A patent/CA2942165C/fr active Active
- 2015-03-06 EP EP15710396.1A patent/EP2970455B1/fr active Active
- 2015-03-06 EP EP16177656.2A patent/EP3095795B1/fr active Active
- 2015-03-06 KR KR1020237018254A patent/KR20230082690A/ko not_active Application Discontinuation
- 2015-03-06 EA EA202090275A patent/EA202090275A3/ru unknown
- 2015-03-06 DK DK16177656.2T patent/DK3095795T3/da active
- 2015-03-06 MX MX2016011628A patent/MX368909B/es active IP Right Grant
- 2015-03-06 ME MEP-2016-264A patent/ME02629B/fr unknown
- 2015-03-06 DK DK15710396.1T patent/DK2970455T3/en active
- 2015-03-06 US US14/641,026 patent/US9079949B1/en active Active
- 2015-03-06 MA MA38859A patent/MA38859B1/fr unknown
- 2015-03-06 JP JP2016555463A patent/JP6112469B1/ja active Active
- 2015-03-06 LT LTEP15710396.1T patent/LT2970455T/lt unknown
- 2015-03-06 HU HUE16177656A patent/HUE046091T2/hu unknown
- 2015-03-06 CN CN201580012081.XA patent/CN106459189B/zh active Active
- 2015-03-06 MA MA050373A patent/MA50373A/fr unknown
- 2015-03-06 ES ES15710396.1T patent/ES2589230T3/es active Active
- 2015-03-06 SI SI201530940T patent/SI3095795T1/sl unknown
- 2015-03-06 IL IL296502A patent/IL296502A/en unknown
- 2015-03-06 PT PT157103961T patent/PT2970455T/pt unknown
- 2015-03-06 EA EA201691764A patent/EA035025B1/ru unknown
- 2015-03-06 EP EP19176561.9A patent/EP3594235A1/fr active Pending
- 2015-06-01 US US14/727,313 patent/US9107861B1/en active Active
- 2015-07-01 US US14/789,329 patent/US9206251B2/en active Active
- 2015-10-27 US US14/923,879 patent/US9371377B2/en active Active
-
2016
- 2016-05-06 HK HK16105197.2A patent/HK1217207A1/zh unknown
- 2016-05-20 US US15/160,364 patent/US9663574B2/en active Active
- 2016-08-17 IL IL247331A patent/IL247331B/en active IP Right Grant
- 2016-09-06 HR HRP20161146TT patent/HRP20161146T1/hr unknown
- 2016-09-07 MX MX2019012455A patent/MX2019012455A/es unknown
- 2016-09-16 CY CY20161100922T patent/CY1118018T1/el unknown
- 2016-10-12 SM SM201600366T patent/SMT201600366B/it unknown
-
2017
- 2017-03-03 JP JP2017040585A patent/JP6894265B2/ja active Active
- 2017-04-20 US US15/492,622 patent/US9803007B1/en active Active
- 2017-09-19 US US15/708,658 patent/US10227400B2/en active Active
-
2019
- 2019-01-14 US US16/246,842 patent/US10584164B2/en active Active
- 2019-05-27 JP JP2019098449A patent/JP7450344B2/ja active Active
- 2019-09-24 AU AU2019236617A patent/AU2019236617B2/en active Active
-
2020
- 2020-01-23 US US16/750,173 patent/US11434280B2/en active Active
- 2020-03-17 IL IL273337A patent/IL273337B/en unknown
- 2020-10-14 JP JP2020173023A patent/JP2021036870A/ja active Pending
- 2020-11-16 AU AU2020267324A patent/AU2020267324B2/en active Active
-
2021
- 2021-11-15 IL IL288139A patent/IL288139A/en unknown
-
2023
- 2023-07-07 US US18/219,138 patent/US20240141024A1/en active Pending
-
2024
- 2024-01-29 JP JP2024011008A patent/JP2024038502A/ja active Pending
- 2024-07-16 AU AU2024204884A patent/AU2024204884A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50373A (fr) | Anticorps anti-c5 présentant une pharmacocinétique améliorée | |
FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
MA47472A (fr) | Anticorps | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
DK3161007T3 (da) | Multispecifikke antistofkonstrukter | |
CL2015000278S1 (es) | Tapa. | |
DK3177634T3 (da) | Modificerede nukleotidlinkere | |
DK3157559T3 (da) | Anti-axl-antistoffer | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
CL2014002537S1 (es) | Tapa. | |
MA42843A (fr) | Anticorps anti-cd115 | |
MA51554A (fr) | Anticorps il-6 améliorés | |
FR3023988B3 (fr) | . | |
MA42137A (fr) | Anticorps vhb anti-pre-s1 | |
DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof | |
DK3215792T3 (da) | Brænder. | |
DK3154587T3 (da) | Konjugater omfattende et anti-egfr1-antistof | |
DK3145536T3 (da) | Modificeret tyrosinammoniaklyase | |
DK3484921T3 (da) | Anti-IL-22R antistoffer | |
MA43869A (fr) | Anticorps anti-myl9 | |
FI20145330A (fi) | Immunomääritys | |
IT201600078684A1 (it) | Fondo anti-varroa | |
TH1501005181A (th) | แอนติบอดีที่ยึดเกาะ il-23 |